Glioblastoma: Background,Standard Treatment Paradigms,and Supportive Care Considerations

Salcman M. , “Long-Term Survival in Patients with Malignant Astrocytoma,” Neurosurgery 34, no. 2 (1994): 213–219;.

Fine H. , “Meta-Analysis of Radiation Therapy with and without Adjuvant Chemotherapy for Malignant Gliomas in Adults,” Cancer 71, no. 8 (1993): 2585–2597;.

Salcman M. , “Survival in Glioblastoma: Historical Perspective,” Neurosurgery 7, no. 5 (1980): 435–439;.

Huncharek M. Muscat J. , “Treatment of Recurrent High Grade Astrocytoma; Results of a Systematic Review of 1,415 Patients,” Anticancer Research 18, no. 2B (1998): 1303–1312;.

Stupp R. , “Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma,” New England Journal of Medicine 352, no. 10 (2005): 987–996;.

Cohen M. , “FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme,” Oncologist 14, no. 11 (2009): 1131–1138;.

“Adult Brain Tumors Treatment (PDQ): Classification of Adult Brain Tumors,” National Cancer Institute, last modified May 14, 2013, available at <http://www.cancer.gov/cancertopics/pdq/treatment/adultbrain/HealthProfessional/page2>(last visited May 13, 2014);.

Avgeropoulos N. Batchelor T. , “New Treatment Strategies for Malignant Gliomas,” The Oncologist 4, no. 3 (1999): 209–224.

Id. ( Salcman , 1994).

Ropper A. Samuels M. , Adams and Victor's Principles of Neurology, 9th ed. (McGraw-Hill Professional, 2009).

Id. ( Fine ).

See Salcman (1994), supra note 1.

See Salcman (1980), supra note 1.

See Salcman (1994), supra note 1;.

Chang S. , Principles and Practice of Neuro-Oncology: A Multidisciplinary Approach, ed. by Mehta M. (Demos Medical, 2010).

See Salcman (1980), supra note 1.

See Fine , supra note 1.

See Salcman (1994), supra note 1;.

Salcman (1980), supra note 1.

See Salcman (1980), supra note 1.

See Huncharek Muscat , supra note 1;.

Delattre J.-Y. , “Erythema Multiforme and Stevens-Johnson Syndrome in Patients Receiving Cranial Irradiation and Phenytoin,” Neurology 38, no. 2 (1988): 194–198.

See Fine , supra note 1.

See Cohen , supra note 1;.

Wood J. , “The Prognostic Importance of Tumor Size in Malignant Gliomas: AComputed Tomographic Scan Study by the Brain Tumor Cooperative Group,” Journal of Clinical Oncology 6, no. 2 (1988): 338–343.

Brandes A. , “Appropriate End-Points for Right Results in the Age of Antiangiogenic Agents: Future Options for Phase II Trials in Patients with Recurrent Glioblastoma,” European Journal of Cancer 48, no. 6 (2012): 896–903.

Macdonald D. , “Response Criteria for Phase II Studies of Supratentorial Malignant Glioma,” Journal of Clinical Oncology 8, no. (1990): 1277–1280.

See Fine , supra note 1.

Id.

Id.

See Fine , supra note 1.

Id.

See Cohen , supra note 1.

See Salcman (1980), supra note 1.

Hospice Patients Alliance, “Karnofsky Performance Status Scale Definitions Rating (%) Criteria,” available at <http://www.hospicepatients.org/karnofsky.html>(last visited March 28, 2014).

Pignatti F. , “Prognostic Factors for Survival in Adult Patients with Cerebral Low-Grade Glioma,” Journal of Clinical Oncology 20, no. 8 (2002): 2076–2084;.

Tabatabai G. , “Molecular Diagnostics of Gliomas: The Clinical Perspective,” Acta Neuropathologica 120, no. 5 (2010): 585–592.

Riemenschneider M. , “MGMTPromoter Methylation in Malignant Gliomas,” Targeted Oncology 5, no. 3 (2010): 161–165;.

Sciuscio D. , “Extent and Patterns of MGMTPromoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres,” Clinical Cancer Research 17, no. 2 (2011): 255–266;.

Weller M. , “MGMTPromoter Methylation in Malignant Gliomas: Ready for Personalized Medicine?” Nature Reviews Neurology 6, no. 1 (2010): 39–51.

Mellinghoff I. , “Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors,” New England Journal of Medicine 353, no. 19 (2005): 2012–2024.

Id.

Ford E. , “Systematic Review of Supportive Care Needs in Patients with Primary Malignant Brain Tumors,” Neuro-Oncology 14, no. 4 (2012): 392–404;.

Brem S. , “Central Nervous System Cancers,” JNCCN 11, no. 6 (2012): 352–400.

Simpson J. , “Influence of Location and Extent of Surgical Resection on Survival of Patients with Glioblastoma Multiforme: Results of Three Consecutive Radiation Therapy Oncology Group (RTOG) Clinical Trials,” International Journal of Radiation Oncology*Biology*Physics* 26, no. 2 (1993): 239–244;.

Lacroix M. , “A Multivariate Analysis of 416 Patients with Glioblastoma Multiforme: Prognosis, Extent of Resection, and Survival,” Journal of Neurosurgery 95, no. 2 (2001): 190–198.

Yabroff R. K. , “Patterns of Care and Survival for Patients with Glioblastoma Multiforme Diagnosed During 2006,” Neuro-Oncology 14, no. 3 (2012): 351–359.

Id.

Laws E. , “Survival Following Surgery and Prognostic Factors for Recently Diagnosed Malignant Glioma: Data from the Glioma Outcomes Project,” Journal of Neurosurgery 99, no. 3 (2003): 467–473.

Perry J. , “Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study,” Journal of Clinical Oncology 28, no. 12 (2010): 2051–2057;.

Stupp R. , “Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial,” The Lancet Oncology 10, no. 5 (2009): 459–466.

Stupp R. , “Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma,” New England Journal of Medicine 352, no. 10 (2005): 987–996.

Mellinghoff I. , “Signal Transduction Inhibitors and Antiangiogenic Therapies for Malignant Glioma,” GLIA59, no. 8 (2011): 1205–1212.

See Perry , supra note 33;.

Stupp , supra note 34;.

Wick A. , “Rechallenge with Temozolomide in Patients with Recurrent Gliomas,” Journal of Neurology 256, no. 5 (2009): 734–741.

See Stupp , supra note 34.

Stupp R. , “Promising Survival for Patients with Newly Diagnosed Glioblastoma Multiforme Treated with Concomitant Radiation plus Temozolomide Followed by Adjuvant Temozolomide,” Journal of Clinical Oncology 20, no. 5 (2002): 1375–1382.

See Stupp , supra note 34.

Groves M. Plummer A. , “Helping Patients Make the Best Decision,” Neuro-oncology 18, no. 2 (2012): 421–425;.

Berrocal A. , “Extended-Schedule Dose-Dense Temozolomide in Refractory Gliomas,” Journal of Neuro-Oncology 96, no. 3 (2010): 417–422.

Hegi M. , “MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma,” New England Journal of Medicine 352 (2005): 997–1003.

Groves M. Plummer A. , “Helping Patients Make the Best Decision Regarding Duration of Temozolomide Chemotherapy Treatment,” Continuum 18, no. 2 (2012): 421–425.

See Stupp , supra note 34.

Id.

Stewart L. , “Chemotherapy in Adult High-Grade Glioma: ASystematic Review and Meta-Analysis of Individual Patient Data from 12 Randomised Trials,” The Lancet 359, no. 9311 (2002): 1011–1018.

See Fine , supra note 1.

Walbert T. , “Combination of 6-Thioguanine, Capecitabine, and Celecoxib with Temozolomide or Lomustine for Recurrent High-Grade Glioma,” Journal of Neuro-Oncology 102, no. 2 (2011): 273–280.

See Cohen , supra note 1.

Murray L. J. Bridgewater C. H. Levy D. , “Carboplatin Chemotherapy in Patients with Recurrent High-Grade Glioma,” Clinical Oncology 23, no. 1 (2011): 55–61.

See Groves Plummer , supra note 41.

Id.

See Cohen , supra note 1.

Gorlia T. , “New Prognostic Factors and Calculators for Outcome Prediction in Patients with Recurrent Glioblastoma: A Pooled Analysis of EORTC Brain Tumour Group Phase I and II Clinical Trials,” European Journal of Cancer 48, no. 8 (2012): 1176–1184.

Dropcho E. J. , “Should the Cost of Care for Patients with Glioblastoma Influence Treatment Decisions?” Continuum 18, no. 2 (2012): 416–420.

Id.

Bai R. Y. , “Molecular Targeting of Glioblastoma: Drug Discovery and Therapies,” Trends in Molecular Medicine 17, no. 6 (2011): 301–312.

See Brandes , supra note 14.

See Bai , supra note 56.

See Dropcho , supra note 54.

Crott R. , “The Economics of Temozolomide in Brain Cancer,” Expert Opinion in Pharmacotherapy 8, no. 12 (2007): 1923–1929.

Calhoun-Eagan R. , “Psychological and Social Impact of Being a Brain Tumor Survivor: Adult Issues,” in Goldman S. Turner C. D. , eds., Late Effects of Treatment for Brain Tumors (New York: Springer Science+Business Media, LLC, 2009): At 309–316.

Stupp R. , “Novocure-TTF-100A Versus Physician's Choice Chemotherapy in Recurrent Glioblastoma: ARandomised Phase III Trial of a Novel Treatment Modality,” European Journal of Cancer 48, no. 14 (2012): 2192–202.

Gehring K. , “Predictors of Neuropsychological Improvement Following Cognitive Rehabilitation in Patients with Gliomas,” Journal of the International Neuropsychological Society 17, no. 2 (2011): 256–266.

Janda M. , “Quality of Life among Patients with a Brain Tumor and Their Careers,” Journal of Psychosomatic Research 63, no. 6 (2007): 617–623.

Id.

Gehring K. , “Interventions for Cognitive Deficits in Patients with a Brain Tumor: An Update,” Expert Reviews of Anticancer Therapy 10, no. 11 (2010): 1779–1795;.

Giovagnoli A. R. , “Investigation of Cognitive Impairments in People with Brain Tumors,” Journal of Neuro-Oncology 108, no. 2 (2012): 277–283.

Gofton T. , “Identifying the Palliative Care Needs of Patients Living with Cerebral Tumors and Metastases: A Retrospective Analysis,” Journal of Neuro-Oncology 108, no. 3 (2012): 527–534.

Grisold W. , “Brain Tumour Treatment: The Concept of Inter- and Multidisciplinary Treatment,” Wiener Medizinische Wochenschrift 156, no. 11–12 (2006): 329–331.

Ford E. , “Systematic Review of Supportive Care Needs in Patients with Primary Malignant Brain Tumors,” Neuro-Oncology 14, no. 4 (2012): 392–404.

Id.